Look beyond the healthcare company's recent setbacks.Several headwinds have pushed Regeneron's (REGN 0.74%) shares lower over the past year and a half. However, the company is bouncing back and has performed well in recent months. What's more, there are two key reasons to think there could be plenty more upside ahead. 1. Moving past Eylea-related issuesArguably, the biggest reason why Regeneron's shares dropped is that competition has intensified for Eylea, its medicine for wet age-related macular degenerat ...